Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

CVRx Announces Chief Financial Officer Transition

CVRx Announces Chief Financial Officer Transition

CVRx, Inc., a NASDAQ-listed medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced that CFO Jared Oasheim will step down to pursue other opportunities but will stay until a successor is appointed and remain an advisor through February 2027. Oasheim has been with the company since 2015 and helped lead…

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics announced positive topline Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in patients with myasthenia gravis (MG), showing significant clinical improvement and good tolerability. The company also initiated a potentially registration-directed Phase 2 trial to evaluate BRIUMVI as maintenance therapy following induction wi…

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharmaceuticals announced a $5 million investment as part of a $13.5 million financing round for its collaboration partner Angel Pharmaceuticals. The funding will support ongoing and upcoming Phase 1b/2 clinical trials of soquelitinib for atopic dermatitis and asthma in China. Corvus retains a significant ownership stake in Angel Pharma and …

QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing

QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing

QTREX Quantum Ltd. announced receiving approximately $1 million from the Israel Innovation Authority to develop a specialized dielectric material optimized for high-density, low-loss RF signal routing in superconducting quantum computers. This development aims to overcome the key scaling challenges in quantum hardware connectivity by integrating ma…

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Alterity Therapeutics announced successful alignment with the U.S. FDA during the End-of-Phase 2 meeting, agreeing on key aspects of the planned Phase 3 clinical trial for ATH434 in treating Multiple System Atrophy (MSA). The FDA approved the study population, dosing regimen, treatment duration, primary and key secondary endpoints, and statistical …

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics has announced a strategic licensing agreement with WestGene Biopharma to combine Cartesian's mRNA CAR-T payload technology with WestGene's targeted lipid nanoparticle platform for in vivo delivery. The partnership aims to initiate Phase 1 clinical trials in the second half of 2026 for generalized myasthenia gravis patients, w…

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Kymera Therapeutics announced the dosing of the first participant in the Phase 1 trial of KT-485, an oral IRAK4 degrader for immuno-inflammatory diseases, conducted by partner Sanofi. This milestone triggered a $20 million payment from Sanofi to Kymera under their collaboration, which includes potential total milestones of up to $975 million. The t…

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies announced that while its management will participate in one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference, CEO Daniel Tassé will not attend the previously scheduled fireside chat due to travel disruptions. The company focuses on developing epicutaneous immunotherapy treatments for food aller…

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion, a healthcare technology company, has partnered with PRIA Healthcare to launch a Market Access Program aimed at advancing reimbursement and commercial adoption of its AI-driven Nociscan platform for chronic low back pain. Building on successful payer approvals in the UK, this initiative seeks to streamline U.S. reimbursement processes and …

17 Education & Technology Group Inc. to Report First Quarter 2026 Unaudited Financial Results on June 16, 2026

17 Education & Technology Group Inc. to Report First Quarter 2026 Unaudited Financial Results on June 16, 2026

17 Education & Technology Group Inc., a leading Chinese education technology company listed on NASDAQ, will release its unaudited first quarter 2026 financial results on June 16, 2026, followed by a management conference call. The company specializes in data-driven teaching and learning solutions and SaaS products to facilitate digital transformati…

Lands’ End Announces First Quarter Fiscal 2026 Results

Lands’ End Announces First Quarter Fiscal 2026 Results

Lands’ End, Inc. announced its first quarter fiscal 2026 results highlighting a temporary operational disruption due to U.S. distribution center upgrades which led to an 8.5% revenue decrease. Despite this, the company showed underlying momentum with increased consumer traffic and strong European growth. A joint venture with WHP Global has improved…

Burning Rock Reports First Quarter 2026 Financial Results

Burning Rock Reports First Quarter 2026 Financial Results

Burning Rock Biotech Limited reported its financial results for Q1 2026, showing an 18.9% year-over-year decrease in total revenue to RMB 107.9 million (US$15.6 million), driven by declines in its central laboratory, in-hospital, and pharma R&D services. The company is transitioning towards in-hospital testing, which impacted test volumes. Gross pr…

Parsons Secures a Total of $218 Million on AFRL GARDEM Contracts

Parsons Secures a Total of $218 Million on AFRL GARDEM Contracts

Parsons Corporation has secured a total of $218 million in contract awards in 2026 to support the Air Force Research Laboratory's Global Application Research, Development, Engineering and Maintenance (GARDEM) mission. The latest $73 million contract expands Parsons' responsibilities for R&D, operations, and maintenance across the GARDEM 2 platform,…

Nathan's Famous, Inc. Reports Year End and Fourth Quarter Results

Nathan's Famous, Inc. Reports Year End and Fourth Quarter Results

Nathan's Famous, Inc. reported its fiscal year 2026 and fourth quarter financial results, showing increased revenues but declines in income from operations and net income compared to the previous fiscal year. The company declared a quarterly cash dividend and provided updates on its merger agreement with Smithfield Foods, which remains subject to r…

Tims China Announces First Quarter 2026 Financial Results

Tims China Announces First Quarter 2026 Financial Results

TH International Limited, the master franchise operator of Tim Hortons in China, announced its Q1 2026 financial results showing a 14.6% decrease in total revenues driven by store closures and lower same-store sales. The company saw a net loss of RMB109.3 million (USD15.8 million), nearly doubling from the previous year, despite growth in loyalty m…

Tims China Announces Appointment of Mr. Kwok Wah Cheung as Chief Executive Officer and Issuance of Additional Senior Secured Convertible Notes

Tims China Announces Appointment of Mr. Kwok Wah Cheung as Chief Executive Officer and Issuance of Additional Senior Secured Convertible Notes

TH International Limited, the exclusive master franchisee of Tim Hortons in China, has appointed Kwok Wah Cheung as its new CEO effective June 15, 2026, succeeding Yongchen Lu who will become Chairman. The company also announced a $55 million issuance of additional senior secured convertible notes to support store expansion and operational funding.…